サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1105626

HIV抗ウイルス薬の世界市場規模調査：製品別、流通チャネル別、地域別予測（2022年～2028年）

Global HIV Antivirals Market Size study, By Product, By Distribution Channel, and Regional Forecasts 2022-2028
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
HIV抗ウイルス薬の世界市場規模調査：製品別、流通チャネル別、地域別予測（2022年～2028年）
出版日: 2022年07月05日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

HIV感染の拡大、HIV治療の選択肢に対する意識の高まり、そして最近の製品発売と規制当局からの承認は、世界市場の需要を加速させる要因となっています。

また、新興国における医療インフラの拡大や、世界各国における政府の積極的な取り組みも、予測期間中の市場需要を喚起する要因の一つになると予想されています。しかし、HIV治療へのアクセスが限られていることや、HIV治療薬の承認に関する厳格な規制ガイドラインが、2022年から2028年の予測期間中における市場成長を阻害すると考えられています。

当レポートでは、世界のHIV抗ウイルス薬市場について調査分析し、市場力学、業界分析、COVID-19の影響、製品別、流通チャネル別、地域別の市場分析、企業プロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界のHIV抗ウイルス薬市場の定義と範囲

第3章 世界のHIV抗ウイルス薬市場力学

  • HIV抗ウイルス薬市場の影響分析(2020年～2028年)

第4章 世界のHIV抗ウイルス薬市場の業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主要な投資機会
  • 主要な成功戦略

第5章 リスク評価:COVID-19の影響

    • COVID-19が業界に与える全体的な影響評価
    • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 世界のHIV抗ウイルス薬市場：製品別

  • 市場のスナップショット
  • 世界のHIV抗ウイルス薬市場実績：製品別 - 潜在的分析
  • 世界のHIV抗ウイルス薬市場の推計と予測：製品別（2018年～2028年）（100万米ドル）
  • HIV抗ウイルス薬市場、サブセグメント分析
    • 固定用量配合剤(FDC)
    • インテグラーゼ鎖転移阻害剤（INSTIs）
    • 非ヌクレオシド系逆転写酵素阻害剤(NNRTI)
    • 侵入阻害剤 - CCR5共受容体拮抗薬
    • プロテアーゼ阻害剤(PI)
    • ヌクレオシド系逆転写酵素阻害剤(NRTI)
    • その他

第7章 世界のHIV抗ウイルス薬市場：流通チャネル別

  • 市場のスナップショット
  • 世界のHIV抗ウイルス薬市場実績：流通チャネル別 - 潜在的分析
  • 世界のHIV抗ウイルス薬市場の推計と予測：流通チャネル別（2018年～2028年）（100万米ドル）
  • HIV抗ウイルス薬市場、サブセグメント分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第8章 世界のHIV抗ウイルス薬市場：地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • その他

第9章 競合情報

  • 主要市場戦略
  • 企業プロファイル
    • ViiV Healthcare
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Genetech, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie
    • Cipla
    • Pfizer Inc.

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global HIV Antivirals Market, report scope
  • TABLE 2. Global HIV Antivirals Market estimates & forecasts by Region 2018-2028 (USD Million)
  • TABLE 3. Global HIV Antivirals Market estimates & forecasts by Product 2018-2028 (USD Million)
  • TABLE 4. Global HIV Antivirals Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
  • TABLE 5. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 6. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 7. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 8. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 9. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 10. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 11. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 12. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 13. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 14. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 15. U.S. HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 16. U.S. HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 17. U.S. HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 18. Canada HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 19. Canada HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 20. Canada HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 21. UK HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 22. UK HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 23. UK HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 24. Germany HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 25. Germany HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 26. Germany HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 27. RoE HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 28. RoE HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 29. RoE HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 30. China HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 31. China HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 32. China HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 33. India HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 34. India HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 35. India HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 36. Japan HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 37. Japan HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 38. Japan HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 39. RoAPAC HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 40. RoAPAC HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 41. RoAPAC HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 42. Brazil HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 43. Brazil HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 44. Brazil HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 45. Mexico HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 46. Mexico HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 47. Mexico HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 48. RoLA HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 49. RoLA HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 50. RoLA HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 51. Row HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 52. Row HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 53. Row HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 54. List of secondary sources, used in the study of global HIV Antivirals Market
  • TABLE 55. List of primary sources, used in the study of global HIV Antivirals Market
  • TABLE 56. Years considered for the study
  • TABLE 57. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global HIV Antivirals Market, research methodology
  • FIG 2. Global HIV Antivirals Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global HIV Antivirals Market, key trends 2021
  • FIG 5. Global HIV Antivirals Market, growth prospects 2022-2028
  • FIG 6. Global HIV Antivirals Market, porters 5 force model
  • FIG 7. Global HIV Antivirals Market, pest analysis
  • FIG 8. Global HIV Antivirals Market, value chain analysis
  • FIG 9. Global HIV Antivirals Market by segment, 2018 & 2028 (USD Million)
  • FIG 10. Global HIV Antivirals Market by segment, 2018 & 2028 (USD Million)
  • FIG 11. Global HIV Antivirals Market by segment, 2018 & 2028 (USD Million)
  • FIG 12. Global HIV Antivirals Market by segment, 2018 & 2028 (USD Million)
  • FIG 13. Global HIV Antivirals Market by segment, 2018 & 2028 (USD Million)
  • FIG 14. Global HIV Antivirals Market, regional snapshot 2018 & 2028
  • FIG 15. North America HIV Antivirals Market 2018 & 2028 (USD Million)
  • FIG 16. Europe HIV Antivirals Market 2018 & 2028 (USD Million)
  • FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
  • FIG 18. Latin America HIV Antivirals Market 2018 & 2028 (USD Million)
  • FIG 19. Global HIV Antivirals Market, company Market share analysis (2021)
目次

Global HIV Antivirals Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The HIV Antivirals refers to antiretroviral medicines utilized to hinder the ability of the human immunodeficiency virus (HIV) to multiply in the body. HIV Antivirals are organized into six different classes based on the stage of the HIV life cycle. The US Food and Drug Administration (FDA) approved more than two dozen antiretroviral drugs to treat HIV infection. The growing prevalence of HIV infection and increasing awareness towards HIV treatment options as well as recent product launches and approvals from regulatory authorities are factors that are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimates - as of 2020, 37.7 million individuals were living with HIV. Around 6,80,000 people succumbs to HIV and another 1.5 million individuals acquired HIV. Moreover, as per United Nations Children's Fund (UNICEF) - in 2020, Globally around 1.72 million children aged 0-14 living with HIV. However, only 54 per cent children received life-saving antiretroviral therapy (ART). Furthermore, other recent factors including new product announcements & recent regulatory approvals are likely to influence the growth of Global HIV Antivirals Market. For instance, in July 2020, the U.S. Food and Drug Administration approved North Carolina, US based ViiV Healthcare's new antiretroviral medication named Rukobia (fostemsavir), intended for adults living with HIV. In addition, in June 2022, Mumbai, India based Cipla Ltd. in collaboration with Geneva, Switzerland based not-for-profit R&D Organization, Drugs for Neglected Diseases initiative (DNDi) launched a new fixed-dose combination of four antiretroviral (ARV) treatment for children living with HIV in South Africa. This new treatment combination is composed of abacavir, lamivudine, lopinavir, and ritonavir and intended for infants and young children. Also, growing healthcare infrastructure in emerging economies and favorable government initiatives across the globe are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, limited access to HIV treatment and rigorous regulatory guidelines for approval of HIV drugs impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global HIV Antivirals Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising government funded programs and presence of recent medications approvals in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing healthcare sector and increasing incidences of HIV infections in the region, would create lucrative growth prospects for the global HIV Antivirals Market across the Asia Pacific region.

Major market players included in this report are:

ViiV Healthcare

Gilead Sciences, Inc.

GlaxoSmithKline plc

Merck & Co., Inc.

Johnson & Johnson

Genetech, Inc.

Teva Pharmaceutical Industries Ltd.

AbbVie

Cipla

Pfizer Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

Fixed Dose Combinations (FDCs)

Integrase Strand Transfer Inhibitors (INSTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Entry Inhibitors - CCR5 co-receptor antagonist

Protease Inhibitors (PIs)

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global HIV Antivirals Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Global HIV Antivirals Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Global HIV Antivirals Market, by Product, 2020-2028 (USD Million)
    • 1.2.3. Global HIV Antivirals Market, by Distribution Channel, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global HIV Antivirals Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global HIV Antivirals Market Dynamics

  • 3.1. HIV Antivirals Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of HIV infection.
      • 3.1.1.2. Increasing awareness towards HIV treatment options.
      • 3.1.1.3. Recent product launches and approvals from regulatory authorities
    • 3.1.2. Market Challenges
      • 3.1.2.1. Limited access to HIV treatment
      • 3.1.2.2. Rigorous regulatory guidelines for approval of HIV drugs.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing healthcare infrastructure in emerging economies.
      • 3.1.3.2. Favourable government initiatives across the globe.

Chapter 4. Global HIV Antivirals Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global HIV Antivirals Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global HIV Antivirals Market by Product, Performance - Potential Analysis
  • 6.3. Global HIV Antivirals Market Estimates & Forecasts by Product 2018-2028 (USD Million)
  • 6.4. HIV Antivirals Market, Sub Segment Analysis
    • 6.4.1. Fixed Dose Combinations (FDCs)
    • 6.4.2. Integrase Strand Transfer Inhibitors (INSTIs)
    • 6.4.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 6.4.4. Entry Inhibitors - CCR5 co-receptor antagonist
    • 6.4.5. Protease Inhibitors (PIs)
    • 6.4.6. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 6.4.7. Others

Chapter 7. Global HIV Antivirals Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global HIV Antivirals Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global HIV Antivirals Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
  • 7.4. HIV Antivirals Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies

Chapter 8. Global HIV Antivirals Market, Regional Analysis

  • 8.1. HIV Antivirals Market, Regional Market Snapshot
  • 8.2. North America HIV Antivirals Market
    • 8.2.1. U.S. HIV Antivirals Market
      • 8.2.1.1. Product estimates & forecasts, 2018-2028
      • 8.2.1.2. Distribution Channel estimates & forecasts, 2018-2028
    • 8.2.2. Canada HIV Antivirals Market
  • 8.3. Europe HIV Antivirals Market Snapshot
    • 8.3.1. U.K. HIV Antivirals Market
    • 8.3.2. Germany HIV Antivirals Market
    • 8.3.3. France HIV Antivirals Market
    • 8.3.4. Spain HIV Antivirals Market
    • 8.3.5. Italy HIV Antivirals Market
    • 8.3.6. Rest of Europe HIV Antivirals Market
  • 8.4. Asia-Pacific HIV Antivirals Market Snapshot
    • 8.4.1. China HIV Antivirals Market
    • 8.4.2. India HIV Antivirals Market
    • 8.4.3. Japan HIV Antivirals Market
    • 8.4.4. Australia HIV Antivirals Market
    • 8.4.5. South Korea HIV Antivirals Market
    • 8.4.6. Rest of Asia Pacific HIV Antivirals Market
  • 8.5. Latin America HIV Antivirals Market Snapshot
    • 8.5.1. Brazil HIV Antivirals Market
    • 8.5.2. Mexico HIV Antivirals Market
  • 8.6. Rest of The World HIV Antivirals Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. ViiV Healthcare
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Gilead Sciences, Inc.
    • 9.2.3. GlaxoSmithKline plc
    • 9.2.4. Merck & Co., Inc.
    • 9.2.5. Johnson & Johnson
    • 9.2.6. Genetech, Inc.
    • 9.2.7. Teva Pharmaceutical Industries Ltd.
    • 9.2.8. AbbVie
    • 9.2.9. Cipla
    • 9.2.10. Pfizer Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption